Advances in molecular targets and cancer therapeutics.
Westwell
Andrew D
AD
Centre for Biomolecular Sciences, School of Pharmacy. University of Nottingham, University Park, Nottingham NG7 2RD, UK. Andrew.Westwell@nottingham.ac.uk
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D001549:Benzamides; D016503:Drug Delivery Systems; D015195:Drug Design; D023281:Genomics / Q000639:trends; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D040901:Proteomics / Q000639:trends; D011743:Pyrimidines / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000639:trends*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate